Research status of receptor-interacting protein kinase 1 in regulating cancer progression and immune response

doi:10.3969/j.issn.1674-8115.2024.06.015

Abstract

Abstract:

Receptor-interacting protein kinase 1 (RIPK1) is a multi-domain serine/threonine protein kinase that causes downstream signal transduction and biological effects by phosphorylating specific proteins. In recent years, with the in-depth study of RIPK1, scholars have found that it is of great significance in autoimmune diseases, neurodegenerative diseases, and a variety of solid tumors and hematological tumors. On the one hand, RIPK1 promotes cell survival and inflammatory responses by activating specific pathways such as nuclear factor-κB (NF-κB) and mitogen-activated protein kinase (MAPK). On the other hand, RIPK1 promotes apoptosis by interacting with cysteinyl aspartate specific proteinase-8 (caspase-8), or promotes necroptosis by interacting with RIPK3 and mixed lineage kinase domain-like protein (MLKL). As an upstream signal, RIPK1 has different expression levels in patients with different tumors. Its scaffold function and kinase activity can regulate cancer progression, initiate adaptive immunity, inhibit tumor progression, and generate an immunosuppressive tumor microenvironment to promote tumor development. Its dual role has been demonstrated in regulating the occurrence and development of tumors and the body's immune response, and can be used as a new therapeutic target to control cancer progression. This paper starts with the structure of RIPK1 to further explore its function in regulating cancer progression and immune response, and to provide new ideas for the development of cancer-targeted drugs.

Key words: receptor-interacting protein kinase 1 (RIPK1), necrotizing apoptosis, necrotic complex, cancer, immune response, targeted therapy

CLC Number:

R730.2

ZHANG Yong, LI Weihong, CHENG Zhipeng, WANG bin, WANG Siheng, WANG Yubin. Research status of receptor-interacting protein kinase 1 in regulating cancer progression and immune response[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(6): 788-794.

TrendMD

References 49

1	DEGTEREV A, HUANG Z H, BOYCE M, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury[J]. Nat Chem Biol, 2005, 1(2): 112-119.
2	SHAN B, PAN H L, NAJAFOV A, et al. Necroptosis in development and diseases[J]. Genes Dev, 2018, 32(5/6): 327-340.
3	DOVEY C M, DIEP J, CLARKE B P, et al. MLKL requires the inositol phosphate code to execute necroptosis[J]. Mol Cell, 2018, 70(5): 936-948.e7.
4	SEIFERT L, WERBA G, TIWARI S, et al. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression[J]. Nature, 2016, 532(7598): 245-249.
5	KONDYLIS V, PASPARAKIS M. RIP kinases in liver cell death, inflammation and cancer[J]. Trends Mol Med, 2019, 25(1): 47-63.
6	YAN J, WAN P X, CHOKSI S, et al. Necroptosis and tumor progression[J]. Trends Cancer, 2022, 8(1): 21-27.
7	MIFFLIN L, OFENGEIM D, YUAN J Y. Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target[J]. Nat Rev Drug Discov, 2020, 19(8): 553-571.
8	LI W J, YUAN J Y. Targeting RIPK1 kinase for modulating inflammation in human diseases[J]. Front Immunol, 2023, 14: 1159743.
9	HE S D, WANG X D. RIP kinases as modulators of inflammation and immunity[J]. Nat Immunol, 2018, 19(9): 912-922.
10	RIEBELING T, KUNZENDORF U, KRAUTWALD S. The role of RHIM in necroptosis[J]. Biochem Soc Trans, 2022, 50(4): 1197-1205.
11	WU G W, LI D K, LIANG W, et al. PP6 negatively modulates LUBAC-mediated M1-ubiquitination of RIPK1 and c-FLIP_L to promote TNFα-mediated cell death[J]. Cell Death Dis, 2022, 13(9): 773.
12	DRABER P, KUPKA S, REICHERT M, et al. LUBAC-recruited CYLD and A20 regulate gene activation and cell death by exerting opposing effects on linear ubiquitin in signaling complexes[J]. Cell Rep, 2015, 13(10): 2258-2272.
13	YUAN J Y, AMIN P, OFENGEIM D. Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases[J]. Nat Rev Neurosci, 2019, 20(1): 19-33.
14	DONDELINGER Y, DARDING M, BERTRAND M J, et al. Poly-ubiquitination in TNFR1-mediated necroptosis[J]. Cell Mol Life Sci, 2016, 73(11/12): 2165-2176.
15	XU D C, JIN T J, ZHU H, et al. TBK1 suppresses RIPK1-driven apoptosis and inflammation during development and in aging[J]. Cell, 2018, 174(6): 1477-1491.e19.
16	WERTZ I, DIXIT V. A20: a bipartite ubiquitin editing enzyme with immunoregulatory potential[J]. Adv Exp Med Biol, 2014, 809: 1-12.
17	GONG Y T, FAN Z Y, LUO G P, et al. The role of necroptosis in cancer biology and therapy[J]. Mol Cancer, 2019, 18(1): 100.
18	LI X M, LI F, ZHANG X X, et al. Caspase-8 auto-cleavage regulates programmed cell death and collaborates with RIPK3/MLKL to prevent lymphopenia[J]. Cell Death Differ, 2022, 29(8): 1500-1512.
19	SALEH D, NAJJAR M, ZELIC M, et al. Kinase activities of RIPK1 and RIPK3 can direct IFN-β synthesis induced by lipopolysaccharide[J]. J Immunol, 2017, 198(11): 4435-4447.
20	LINKERMANN A, GREEN D R. Necroptosis[J]. N Engl J Med, 2014, 370(5): 455-465.
21	LIU T J, ZONG H F, CHEN X Y, et al. Toll-like receptor 4-mediated necroptosis in the development of necrotizing enterocolitis[J]. Pediatr Res, 2022, 91(1): 73-82.
22	BRISSE M, LY H. Comparative structure and function analysis of the RIG-I-like receptors: RIG-I and MDA5[J]. Front Immunol, 2019, 10: 1586.
23	ZHANG T, YIN C R, BOYD D F, et al. Influenza virus Z-RNAs induce ZBP1-mediated necroptosis[J]. Cell, 2020, 180(6): 1115-1129.e13.
24	LIN J, KUMARI S, KIM C, et al. RIPK1 counteracts ZBP1-mediated necroptosis to inhibit inflammation[J]. Nature, 2016, 540(7631): 124-128.
25	DEGTEREV A, OFENGEIM D, YUAN J Y. Targeting RIPK1 for the treatment of human diseases[J]. Proc Natl Acad Sci U S A, 2019, 116(20): 9714-9722.
26	DILLON C P, WEINLICH R, RODRIGUEZ D A, et al. RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3[J]. Cell, 2014, 157(5): 1189-1202.
27	IMANISHI T, UNNO M, YONEDA N, et al. RIPK1 blocks T cell senescence mediated by RIPK3 and caspase-8[J]. Sci Adv, 2023, 9(4): eadd6097.
28	YATIM N, JUSFORGUES-SAKLANI H, OROZCO S, et al. RIPK1 and NF-κB signaling in dying cells determines cross-priming of CD8⁺ T cells[J]. Science, 2015, 350(6258): 328-334.
29	MANDAL R, BARRÓN J C, KOSTOVA I, et al. Caspase-8: the double-edged sword[J]. Biochim Biophys Acta Rev Cancer, 2020, 1873(2): 188357.
30	WU B Y, LI J Y, WANG H, et al. RIPK1 is aberrantly expressed in multiple B-cell cancers and implicated in the underlying pathogenesis[J]. Discov Oncol, 2023, 14(1): 131.
31	CAO L Y, MU W. Necrostatin-1 and necroptosis inhibition: pathophysiology and therapeutic implications[J]. Pharmacol Res, 2021, 163: 105297.
32	KATSUYA K, OIKAWA D, IIO K, et al. Small-molecule inhibitors of linear ubiquitin chain assembly complex (LUBAC), HOIPINs, suppress NF- κB signaling[J]. Biochem Biophys Res Commun, 2019, 509(3): 700-706.
33	WANG Y K, MA N, XU S, et al. PPDPF suppresses the development of hepatocellular carcinoma through TRIM21-mediated ubiquitination of RIPK1[J]. Cell Rep, 2023, 42(4): 112340.
34	JUNG S Y, PARK J I, JEONG J H, et al. Receptor interacting protein 1 knockdown induces cell death in liver cancer by suppressing STAT3/ATR activation in a p53-dependent manner[J]. Am J Cancer Res, 2022, 12(6): 2594-2611.
35	YU Y Q, THONN V, PATANKAR J V, et al. SMYD2 targets RIPK1 and restricts TNF-induced apoptosis and necroptosis to support colon tumor growth[J]. Cell Death Dis, 2022, 13(1): 52.
36	LIN P H, LIN C L, HE R F, et al. TRAF6 regulates the abundance of RIPK1 and inhibits the RIPK1/RIPK3/MLKL necroptosis signaling pathway and affects the progression of colorectal cancer[J]. Cell Death Dis, 2023, 14(1): 6.
37	BAI W Q, CUI F J, WANG Z H, et al. Receptor-interacting protein kinase 1 (RIPK1) regulates cervical cancer cells via NF-κB-TNF-α pathway: an in vitro study[J]. Transl Oncol, 2023, 36: 101748.
38	KHAMSEH M E, SHEIKHI A, SHAHSAVARI Z, et al. Evaluation of the expression of necroptosis pathway mediators and its association with tumor characteristics in functional and non-functional pituitary adenomas[J]. BMC Endocr Disord, 2022, 22(1): 1.
39	PATEL S, WEBSTER J D, VARFOLOMEEV E, et al. RIP1 inhibition blocks inflammatory diseases but not tumor growth or metastases[J]. Cell Death Differ, 2020, 27(1): 161-175.
40	HÄNGGI K, VASILIKOS L, VALLS A F, et al. RIPK1/RIPK3 promotes vascular permeability to allow tumor cell extravasation independent of its necroptotic function[J]. Cell Death Dis, 2017, 8(2): e2588.
41	LI Y S, XIONG Y, ZHANG G, et al. Identification of 5-(2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as a new class of receptor-interacting protein kinase 1 (RIPK1) inhibitors, which showed potent activity in a tumor metastasis model[J]. J Med Chem, 2018, 61(24): 11398-11414.
42	ZHU G W, DU Q, CHEN X, et al. Receptor-interacting serine/threonine-protein kinase 1 promotes the progress and lymph metastasis of gallbladder cancer[J]. Oncol Rep, 2019, 42(6): 2435-2449.
43	MCCORMICK K D, GHOSH A, TRIVEDI S, et al. Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma[J]. Carcinogenesis, 2016, 37(5): 522-529.
44	CUCHET-LOURENÇO D, ELETTO D, WU C X, et al. Biallelic RIPK1 mutations in humans cause severe immunodeficiency, arthritis, and intestinal inflammation[J]. Science, 2018, 361(6404): 810-813.
45	LI Y, FÜHRER M, BAHRAMI E, et al. Human RIPK1 deficiency causes combined immunodeficiency and inflammatory bowel diseases[J]. Proc Natl Acad Sci U S A, 2019, 116(3): 970-975.
46	LALAOUI N, BOYDEN S E, ODA H, et al. Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease[J]. Nature, 2020, 577(7788): 103-108.
47	TAO P F, SUN J Q, WU Z M, et al. A dominant autoinflammatory disease caused by non-cleavable variants of RIPK1[J]. Nature, 2020, 577(7788): 109-114.
48	AAES T L, KACZMAREK A, DELVAEYE T, et al. Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity[J]. Cell Rep, 2016, 15(2): 274-287.
49	CUCOLO L, CHEN Q Z, QIU J Y, et al. The interferon-stimulated gene RIPK1 regulates cancer cell intrinsic and extrinsic resistance to immune checkpoint blockade[J]. Immunity, 2022, 55(4): 671-685.e10.

[1]	PAERHATI Nadina, ZHANG Pengshan, XU Yitian, CHEN Yunqi, HUANG Chen. Construction of a truncated cylindromatosis tumor suppressor deubiquitinase plasmid and its regulation of the phenotypes of gastric cancer cells [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(9): 1149-1160.
[2]	WANG Jingyi, DENG Jiali, ZHU Yi, DING Xinyi, GUO Jiajing, WANG Zhongling. Experimental study on novel pH-responsive manganese-based nanoprobes for ferroptosis and magnetic resonance imaging in breast cancer [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(9): 1183-1193.
[3]	YIN Ziming, WANG Rongqin, YANG Ziyi, LIU Yingbin, CHEN Tao, SHU Yijun, GONG Wei. Graph neural network-based auxiliary diagnostic model for gallbladder cancer on CT imaging [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(9): 1221-1231.
[4]	JIANG Yi, HUANG Chenhao, LI Zhiliang, WU Junwei, ZHAO Ren, ZHANG Tao. Effect of preoperative chemotherapy combined with immunotherapy in a colorectal cancer patient with KRAS mutation [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(9): 1256-1260.
[5]	HUANG Xin, LIU Jiahui, YE Jingwen, QIAN Wenli, XU Wanxing, WANG Lin. Development and clinical application of a machine learning-driven model for metabolite-based diagnosis of small cell lung cancer [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(8): 1009-1016.
[6]	ZHANG Yuqin, AIHEMAITI Yilixiati, WANG Yanli, YANG Zhi, HUANG Jian. Ubiquitination and degradation of RPTPα mediated by MARCH9 [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(8): 957-968.
[7]	AIMAITI Muerzhate, ZHANG Yeqian, LIU Tao, BAI Long, ZHANG Haoyu, NI Bo, GUAN Yujing, WANG Shuchang, GU Jiayi, ZHU Chunchao, XIA Xiang, ZHANG Zizhen. A comparative analysis of the short-term efficacy of robotic and laparoscopic proximal gastrectomy combined with double-flap anastomosis in the treatment of early upper gastric cancer [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(7): 874-882.
[8]	WANG Rui, YUAN Ying, TAO Xiaofeng. Application value of synthetic magnetic resonance imaging in predicting cervical lymph node metastasis of oral cancer [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(7): 900-909.
[9]	YANG Na, LIU Junli, BAI Jing, YANG Siyi, HAN Jiming, ZHANG Huahua. HENMT1 promotes the proliferation and migration of gastric cancer by activating the PI3K-AKT-mTOR signaling pathway [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(6): 717-726.
[10]	TANG Kairan, FENG Chengling, HAN Bangmin. Integrated single-cell and transcriptome sequencing to construct a prognostic model of M2 macrophage-related genes in prostate cancer [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(5): 549-561.
[11]	YU Kai, SHUAI Zhewei, HUANG Hongjun, LUO Yan. Research progress on the role and mechanisms of microglia in inflammatory diseases of central nervous system [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(5): 630-638.
[12]	MAO Chenzhou, ZHANG Ruiyun, CHEN Haige, YIN Fangfei, ZUO Xiaolei. Framework nucleic acid-based linear amplification platform for sensitive detection of bladder cancer-related miRNAs [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(3): 253-260.
[13]	DENG Jiali, GUO Jiajing, WANG Jingyi, DING Xinyi, ZHU Yi, WANG Zhongling. Self -assembled drug -loaded nanoprobes for pyroptosis sensitization and chemical exchange saturation transfer imaging in breast cancer [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(3): 271-281.
[14]	CHEN Jiaying, CHU Yimin, PENG Haixia. Study on prediction model and influencing factors of progression-free survival in colorectal cancer [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(3): 324-334.
[15]	ZOU Peichen, LIU Hongyu, AIHEMAITI· Ayinazhaer, ZHU Liang, TANG Yabin, LEI Huimin. Metabolic profiling of lung cancer cells with acquired resistance to sotorasib [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(2): 138-149.